secwatch.observer — SEC 8-K summary
======================================

Issuer:     Voyager Therapeutics, Inc. (VYGR)
CIK:        0001640266
Form:       8-K
Filed at:   2026-03-09T23:59:59+00:00
Accession:  0001104659-26-025201
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Voyager Q4 2025 net loss $27.4M, cash $201.7M; key pipeline milestones H2 2026
------------------------------------------------------------------------------

- Q4 2025 net loss $27.4M vs $34.5M in Q4 2024; full year net loss $119.7M vs $65.0M.
- Collaboration revenue Q4 $15.3M (up 143% YoY) but full year $40.4M (down 50% YoY).
- Cash $201.7M at Dec 31 2025; runway expected into 2028 with up to $2.4B in milestone potential.
- VY1706 (tau-silencing) IND planned Q2 2026, first-in-human dosing H2 2026; VY7523 tau PET data H2 2026.
- APOE gene therapy program paused; Neurocrine milestone $3M triggered in Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1640266/000110465926025201/0001104659-26-025201-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1640266/000110465926025201/vygr-20260309x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-025201

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer